Group purchasing organization Novation inked a pair of new contracts with medical device companies AccuVein and MYCO.
Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at startup HeartFlow.
Venipuncture – drawing blood or establishing an intravenous feed – is the most common invasive medical procedure. For many patients, it’s a painful exercise in frustration when clinicians struggle to find a blood vessel, sometimes requiring multiple needle sticks.
AccuVein and CEO Ron Goldman aim to change all that with the company’s AV300 vascular illumination device. The wireless, handheld module uses a pair of lasers to paint a patient’s arm with light, making otherwise invisible or hard-to-find blood vessels apparent to the naked eye.
Medtronic Inc. (NYSE:MDT) won CE Mark approval in the European for its percutaneous aortic valve replacement system, CoreValve.
The device is "the only transcatheter aortic valve available in the world that can treat – without surgery – patients with larger valve openings (up to 29mm)," according to a press release.
CoreValve is the largest transcatheter valve available, but can compress into a small delivery system to be deployed in the same delivery system as smaller CoreValve sizes.
Baxter International Inc. (NYSE: BAX) put aside $200 million in equity to invest in early-stage companies that "complement" its portfolio.
The newly established " Baxter Ventures will invest globally and focus on innovative technologies with sustainable long-term growth" under the watch of the Deerfield, Ill.-based company’s chief scientific officer Norbert Riedel, according to a press release.